(MENAFN- GlobeNewsWire - Nasdaq) Partnership Delivers Advanced Radioligand Treatments Across Asia-Pacific, Expanding Access to Cutting-Edge Cancer Therapies
TAIPEI, Taiwan, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Primo Biotechnology ("Primo") has announced a strategic partnership with SHINE Technologies, LLC ("SHINE"), a global leader in nuclear medicine production. This agreement grants Primo exclusive distribution rights for IlumiraTM (n.c.a. lutetium-177, Lu-177) in Taiwan and additional sales rights in Japan, South Korea, and Singapore. The collaboration aims to accelerate advancements in radioligand therapy (RLT), improving access to cutting-edge cancer treatments in the Asia-Pacific region.
IlumiraTM offers a transformative solution in nuclear medicine, enabling precise and effective treatments for challenging tumors. Primo's comprehensive solutions will address the growing demand for advanced cancer therapies, from early diagnosis to late-stage treatment.
Under the partnership, Primo will gain priority access to SHINE's therapeutic isotopes, ensuring a reliable supply for emerging nuclear medicine applications. SHINE's Cassiopeia facility, North America's largest n.c.a. Lu-177 production site, is expanding to meet the increasing global demand, strengthening SHINE's position as a leading supplier and enhancing Primo's market presence.
“This collaboration marks a pivotal step in bringing precision and hope to patients across Asia-Pacific,” said Dr. Ya-Yao Huang, CEO of Primo Biotechnology.“By partnering with SHINE, we ensure a stable supply of high-quality isotopes and advance cancer care in the region.”
About SHINE
Based in Janesville, Wisconsin, SHINE specializes in the production of n.c.a. Lu-177 and other medical isotopes. Through innovative fusion technology, SHINE is advancing cancer treatment and diagnostics while exploring applications in healthcare and sustainable energy. Learn more at
About Primo Biotechnology
Primo Biotechnology is a leader in Asia's nuclear medicine sector, dedicated to developing and delivering high-precision radiopharmaceuticals. Committed to personalized cancer care, Primo's vision, Future in Precision, drives its mission to improve healthcare outcomes. Visit for more information.
Media Contact:
Primo Biotechnology Co., Ltd.
Sunny Chen
Marketing Manager
... | +8862-2537-1160
A photo accompanying this announcement is available at
MENAFN08012025004107003653ID1109070377
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.